No Cardiac Benefit for Omega-3 Fatty Acids

Article

A systematic review and meta-analysis of 20 studies representing experience in 68,680 patients shows that use of omega-3 fatty acid supplementation does not improve cardiovascular risk factors. Published in The Journal of the American Medical Association, the report examined evidence from randomized clinical trials (RCTs) in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from as early as 1989 through August 2012.

A systematic review and meta-analysis of 20 studies representing experience in 68,680 patients shows that use of omega-3 fatty acid supplementation does not improve cardiovascular risk factors. Published in The Journal of the American Medical Association, the report examined evidence from randomized clinical trials (RCTs) in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from as early as 1989 through August 2012.

The RCTs included omega-3 administration and diet or placebo for primary or secondary cardiovascular disease (CVD). Studies with treatment duration less than 1 year were excluded to ensure sufficient time to prove efficacy of treatment in CVD prevention. The researchers also evaluated the methodological quality of the trials and assessed the risk of bias, using the Cochrane collaboration tool.

Most of the study participants were of European ancestry (15 studies; 49,314 participants) but the largest trial included 18,645 Japanese participants. In all but two trials, omega-3 supplements were used, at a mean dosage of 1.51 g/day; mean treatment duration was 2 years.

When all supplement studies were considered, no statistically significant association was observed for all-cause mortality (relative risk [RR], 0.96; 95% CI, 0.91 to 1.02; risk reduction [RD] -0.004, 95% CI, -0.01 0.02), cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; RD -0.01; 95% CI, -0.02 to 0.00), sudden death (RR, 0.87; 95% CI, 0.75 to 1.01; RD, -0.003, 95% CI, -0.012 to 0.006), myocardial infarction (RR, 0.89; 95% CI, 0.76 to 1.04; RD, -0.002; 95% CI, -0.007 to 0.002), or stroke (RR, 1.05; 95% CI, 0.93 to 1.18; RD, 0.001; 95% CI, -0.002 to 0.004). Neither study-specific nor population-specific characteristics were associated with the observed effect of omega-3.

Read other articles in this issue of Special Delivery.

Recent Videos
Expert discussions from the 2025 ACOG meeting | Image Credit: © stevengaertner - © stevengaertner - stock.adobe.com.
Trina Mansour, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Lisa Bayer, MD, MPH
Megan Wasson, DO, FACOG
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Wasson and Colak
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
© 2025 MJH Life Sciences

All rights reserved.